Author

V. Feuillet

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Organism:human· 1 Assay:imaging· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Trautmann· 2 shared E. Donnadieu· 2 shared F. Regnier· 2 shared G. Bismuth· 2 shared L. Vimeux· 2 shared N. Bercovici· 2 shared A. Benabid· 1 shared A. Fraisse· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Trautmann

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

cAMP bursts control T cell directionality by actin cytoskeleton remodeling

M. Simao, F. Regnier, S. Taheraly, A. Fraisse, R. Tacine, M. Fraudeau, A. Benabid, V. Feuillet, M. Lambert, J. Delon, c. randriamampita

The paper shows that cAMP bursts from the leading edge of T cells drive actin remodeling, which is necessary for directional migration.

bioRxiv · Jul 6, 2020Immunology

TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors

M. V. V. Guerin, F. Regnier, V. Feuillet, L. Vimeux, J. M. Weiss, G. Bismuth, G. Altan-Bonnet, T. Guilbert, M. Thoreau, V. Finisguerra, E. Donnadieu, A. Trautmann, N. Bercovici

This study shows that TGFβ inhibits IFNα/β production and tumor rejection in spontaneous mammary tumors, and blocking TGFβ enhances DMXAA-induced tumor regression.

bioRxiv · Jul 9, 2019Cancer Biology

Blockade of β-adrenergic receptor signaling improves cancer vaccine efficacy through its effect on naive CD8+ T-cell priming

C. Daher, L. Vimeux, R. Stoeva, E. Peranzoni, G. Bismuth, E. Donnadieu, N. Bercovici, A. Trautmann, V. Feuillet

This study shows that blocking β-adrenergic receptor signaling enhances cancer vaccine efficacy by improving naive CD8+ T-cell priming, without affecting tumor-infiltrating CD8+ T-cell reactivity.

bioRxiv · Dec 16, 2018 · PreprintImmunology